|
|
|
|
Merck spent $1.8M lobbying gov't in 4Q, up 38 pct
WASHINGTON Pharmaceutical company Merck & Co.spent $1.82 million lobbying the federal government on drug pricing, patent reform, funding for its products and health care reform in the fourth quarter, according to a recent disclosure form. That was up...
|
|
|
Merck spent $1.8M lobbying gov't in 4Q, up 38 pct
WASHINGTON Pharmaceutical company Merck & Co.spent $1.82 million lobbying the federal government on drug pricing, patent reform, funding for its products and health care reform in the fourth quarter, according to a recent disclosure form. That was up...
|
|
|
Merck spent $1.8 million in 4Q lobbying federal government on drug pricing, health overhaul
WASHINGTON Pharmaceutical company Merck & Co.spent $1.82 million lobbying the federal government on drug pricing, patent reform, funding for its products and health care reform in the fourth quarter, according to a recent disclosure form. That was up...
|
|
|
To Take on Botox, Rival Tries Rebate
Medicis is offering more than rebates on its own product.For customers who feel unsatisfied after trying Dysport, the company is also offering a rebate on a treatment with Allergans Botox. We are so confident that we are literally willing to bet our money...
|
|
|
To take on Botox, rival tries rebate
Allergan and Medicis Pharmaceutical are the Coke and Pepsi of vanity medicine.Allergan makes Botox Cosmetic, the well-known injectable anti-wrinkle treatment. Medicis markets Dysport, a competing anti-wrinkle shot, in the United States. The Food and Drug...
|
|
|
To Take on Botox, Rival Tries Rebate
This copy is for your personal, noncommercial use only.You can order presentation-ready copies for distribution to your colleagues, clients or customers here or use the 'Reprints' tool that appears above any article. Allergan and Medicis Pharmaceutical are...
|
|
|
Rival Medicis takes on Allergan's Botox
Natasha Singer The New York Times News Service Published on Friday, Mar.12, 2010 11:04AM EST A Allergan makes Botox Cosmetic, the well-known injectable anti-wrinkle treatment. Medicis markets Dysport, a competing anti-wrinkle shot, in the United States.
|
|
|
Wrinkle Wars: Rival Medicis takes on Allergan's Botox
A doctor in Arlington, Va., injects Botox Maker of Dysport offers aggressive rebates in marketing campaign Email Please enter a valid e-mail address Please enter a comma delimited list of valid e-mail addresses Other ways of sharing: License this story...
|
|
|
To Take on Botox, Rival Tries Rebate
We are so confident that we are literally willing to bet our money that patients will love their Dysport treatment, said Jonah Shacknai, the chief executive of Medicis.The Dysport campaign, which runs through April 30, is thought to be the first time a drug...
|
|
|
To Take on Botox, Rival Tries Rebate
Allergan and Medicis Pharmaceutical are the Coke and Pepsi of vanity medicine.Medicis Pharmaceuticals is turning aggressive in its marketing, offering $75 off treatments with the wrinkle drug Dysport. Allergan makes Botox Cosmetic, the well-known...
|
|
|
Dysport Takes On Botox With Aggressive Rebates
Allergan and Medicis Pharmaceutical are the Coke and Pepsi of vanity medicine.Medicis Pharmaceuticals is turning aggressive in its marketing, offering $75 off treatments with the wrinkle drug Dysport. Allergan makes Botox Cosmetic, the well-known...
|
|
|
Market steady; Teva and Camtek patent cases in focus
By Robert Daniel, MarketWatch TEL AVIV (MarketWatch) -- Israel stocks were little changed on Sunday, led by weakness in Israel Chemicals and offset by a positive move in Teva Pharmaceutical.Late in the trading day, the Tel Aviv Stock Exchange's benchmark TA...
|
|
|
Detecting Vocal Cord Dysfunction With Coexisting Asthma
'Tina' is a 12-year-old girl with a known history of asthma and seasonal allergic rhinitis who presents to our office complaining of 2 days of shortness of breath, wheezing and fatigue that interfered with her activities and school attendance.She has a...
|
|
|
NIH Study Looks At Long-Acting Asthma Drugs For Children
WASHINGTON -(Dow Jones)- A study found that certain long-acting asthma drugs such as GlaxoSmithKline PLC's (GSK, GSK.LN) Advair were more likely to be the best add-on therapy for children whose asthma isn't well controlled by other drugs.The study, funded by...
|
|
|
Merck Asthma Treatment Shows Positive Results In Study
DOW JONES NEWSWIRES Merck & Co.'s(MRK) investigational asthma treatment that combines two medications was more effective in staving off the need for emergency treatment and improving lung function in late-stage trials than either drug alone.The data...
|
|
|
NIH Study Looks At Long-Acting Asthma Drugs For Children
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- A study found that certain long-acting asthma drugs such as GlaxoSmithKline PLC's (GSK, GSK.LN) Advair were more likely to be the best add-on therapy for children whose asthma isn't well...
|
|
|
NIH Study Looks At Long-Acting Asthma Drugs For Children
WASHINGTON -(Dow Jones)- A study found that certain long-acting asthma drugs such as GlaxoSmithKline PLC's (GSK, GSK.LN) Advair were more likely to be the best add-on therapy for children whose asthma isn't well controlled by other drugs.The study, funded by...
|
|
|
The top Dow dividend stocks
Here are profiles of the top five dividend-paying stocks on the Dow at present.AP 5 - Kraft KFT-N Market Cap: $43 billion Dividend: $0.29 Yield: 3.9 per cent After consistently raising dividends every year since it went public in 2001, Kraft Foods hit the...
|
|
|
Merck Asthma Treatment Shows Positive Results In Study (DJ)
Merck Asthma Treatment Shows Positive Results In Study DOW JONES NEWSWIRES Merck & Co.'s (MRK) investigational asthma treatment that combines two medications was more effective in staving off the need for emergency treatment and improving lung function in...
|
|
|
Merck: Mergers and Layoffs and Pipelines, Oh My!
Merck CEO and president Richard Clark has expressed satisfaction with the new Merck.So far, he has good reason, as earnings were slightly higher than analysts predicted. The strong performance of HIV drug Isentress, which posted a 108 percent increase in...
|
|
|
Singulair helps prevent wheezing after RSV bronchiolitis
South Korean researchers said montelukast, or Singulair, can help prevent recurr Singulair helps prevent wheezing after RSV bronchiolitis.
|
|
|
Medcos Snow: More Original Research to Aid Care, Cut Costs
Pharmacy-benefit manager Medco Health Solutions reported earnings today, and the results didnt seem to surprise Wall Street too much even though its shares declined.But the company took some time on its call with analysts to highlight its growing push into...
|
|
|
Medcos Snow: More Original Research to Aid Care, Cut Costs
Pharmacy-benefit manager Medco Health Solutions reported earnings today, and the results didnt seem to surprise Wall Street too much even though its shares declined.But the company took some time on its call with analysts to highlight its growing push into...
|
|
|
UPDATE: US Patent Office Tentatively Rejects Plavix Claims
(Adds comment from Bristol-Myers in 4th paragraph; adds stock price in last graph.) By Peter Loftus Of DOW JONES NEWSWIRES The U.S.Patent and Trademark Office has tentatively rejected certain claims in a key patent for blockbuster anti-clotting drug Plavix,...
|
|
|
UPDATE: US Patent Office Tentatively Rejects Plavix Claims
(Adds comment from Bristol-Myers in 4th paragraph; adds stock price in last graph.) Of DOW JONES NEWSWIRES The U.S.Patent and Trademark Office has tentatively rejected certain claims in a key patent for blockbuster anti-clotting drug Plavix, which is co...
|
